Scholarlink

Purpose <p>To estimate the prevalence of BALAD in Treatment Naïve nAMD patients in the PRECISE study and report the response after loading phase of 2 mg aflibercept treatment.</p> Methods <p>The PRECISE study included patients aged above 50 years with treatment naïve nAMD and a baseline visual acuity (VA) between 24 and 78 letters ETDRS. All participants received three monthly aflibercept 2 mg injections followed by 8-week post-treatment follow up. BALAD prevalence, baseline clinical characteristics and the visual and anatomical response to aflibercept loading were evaluated.</p> Results <p>Among the 1981 eligible eyes, BALAD was observed in 69 eyes (3.6%). BALAD was found in 2.7% of eyes with type 1 MNV, 6.8% of eyes with type 2 MNV, 0.5% of eyes with retinal angiomatous proliferation (RAP) and in 1.6% of eyes with polypoidal choroidal vasculopathy (PCV) (<i>p</i> &lt; 0.0001). Eyes with BALAD at baseline had significantly lower VA and higher CST compared to eyes without BALAD. BALAD resolved in 63 out of 69 eyes (91.3%). VA improved and CST reduced post-treatment. Fibrosis was observed in 28 (40.6%) and ellipsoid zone disruption in 55 (79.7%) out of 69 eyes in the final visit.</p> Conclusions <p>This study estimated that BALAD was present in 3.6% of eyes with treatment naïve nAMD and occurred more frequently in type 2 MNV. Although BALAD resolved in 91.3% of eyes and visual and anatomical recovery was achieved, eyes with BALAD showed a frequent early association with fibrosis and ellipsoid zone disruption at the post-loading phase visit.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence of bacillary layer detachment (BALAD) in treatment naive neovascular age-related macular degeneration (nAMD) and response to treatment after loading phase of aflibercept 2 mg: PRECISE study report 9

  • 期刊论文

  • 发表日期：

    2026年6月23日

查看全文
  • Dimitrios Kazantzis,
  • Ayse Merve Keskin,
  • Sridevi Thottarath,
  • Heena Syed Kubravi,
  • Abhishek Sheemar,
  • Sobha Sivaprasad

摘要

Purpose

To estimate the prevalence of BALAD in Treatment Naïve nAMD patients in the PRECISE study and report the response after loading phase of 2 mg aflibercept treatment.

Methods

The PRECISE study included patients aged above 50 years with treatment naïve nAMD and a baseline visual acuity (VA) between 24 and 78 letters ETDRS. All participants received three monthly aflibercept 2 mg injections followed by 8-week post-treatment follow up. BALAD prevalence, baseline clinical characteristics and the visual and anatomical response to aflibercept loading were evaluated.

Results

Among the 1981 eligible eyes, BALAD was observed in 69 eyes (3.6%). BALAD was found in 2.7% of eyes with type 1 MNV, 6.8% of eyes with type 2 MNV, 0.5% of eyes with retinal angiomatous proliferation (RAP) and in 1.6% of eyes with polypoidal choroidal vasculopathy (PCV) (p < 0.0001). Eyes with BALAD at baseline had significantly lower VA and higher CST compared to eyes without BALAD. BALAD resolved in 63 out of 69 eyes (91.3%). VA improved and CST reduced post-treatment. Fibrosis was observed in 28 (40.6%) and ellipsoid zone disruption in 55 (79.7%) out of 69 eyes in the final visit.

Conclusions

This study estimated that BALAD was present in 3.6% of eyes with treatment naïve nAMD and occurred more frequently in type 2 MNV. Although BALAD resolved in 91.3% of eyes and visual and anatomical recovery was achieved, eyes with BALAD showed a frequent early association with fibrosis and ellipsoid zone disruption at the post-loading phase visit.